NKG2D (natural killer group 2, member D) is an activating receptor found on the surface of immune cells, including natural killer (NK) cells, which regulates innate and adaptive immunity through recognition of the stress-induced ligands ULBP1 (UL16 binding protein 1) to ULBP6 and MICA/B. Similar to class I human leukocyte antigen (HLA), these NKG2D ligands have a major histocompatibility complex-like fold and exhibit pronounced polymorphism, which influences human disease susceptibility. However, whereas class I HLA polymorphisms occur predominantly in the a1a2 groove and affect antigen binding, the effects of most NKG2D ligand polymorphisms are unclear. We studied the molecular and functional consequences of the two major alleles of ULBP6, the most polymorphic ULBP gene, which are associated with autoimmunity and relapse after stem cell transplantation. Surface plasmon resonance and crystallography studies revealed that the arginine-to-leucine polymorphism within ULBP0602 affected the NKG2D-ULBP6 interaction by generating an energetic hotspot. This resulted in an NKG2D-ULBP0602 affinity of 15.5 nM, which is 10-to 1000-fold greater than the affinities of other ULBP-NKG2D interactions and limited NKG2D-mediated activation. In addition, soluble ULBP0602 exhibited high-affinity competitive binding for NKG2D and partially suppressed NKG2D-mediated activation of NK cells by other NKG2D ligands. These effects resulted in a decrease in a range of NKG2D-mediated effector functions. Our results reveal that ULBP polymorphisms affect the strength of human lymphocyte responses to cellular stress signals and may offer opportunities for therapeutic intervention.
INTRODUCTION
NKG2D is a major activating receptor on cytotoxic immune cells and plays an important role in innate immunity and stress surveillance. Conserved between mice and humans, NKG2D is found on a range of cytotoxic immune cells, including natural killer (NK) cells, gd T cells, NKT cells, and ab T cell subsets (1) . A key feature of NKG2D is its interaction with many different NKG2D ligands on the surface of target cells. In humans, the main NKG2D ligands are MICA/B and the UL16 binding proteins (ULBPs), whereas in mice, they consist of the RAET1, MULT-1, and H60 proteins (2) (3) (4) (5) . The amounts of NKG2D ligands at the cell surface increase during times of cellular stress, such as during viral infection (for example, with cytomegalovirus) (6) and tumorigenesis (7) (8) (9) (10) . Tumor cells and viruses evoke a range of mechanisms to evade recognition by NKG2D (5, (11) (12) (13) , highlighting the importance of this system of "lymphoid stress surveillance." NKG2D ligands are also found on dendritic cells and myeloid cell subsets (14) (15) (16) , which suggests a potentially important influence of the NKG2D ligand pathway on the link between innate and adaptive immunity.
NKG2D homodimers bind to NKG2D ligands in an interaction that is analogous to that seen in T cell receptor (TCR)-major histocompatibility complex (MHC) class I complexes (17) . A striking feature of NKG2D ligand-encoding genes is their high rate of polymorphism (18) (19) (20) (21) , which mirrors the more extensive polymorphism observed within classical MHC-encoding genes. Polymorphisms in the MHC-encoding genes are clustered mainly around the region encoding the antigen-binding groove, and they influence both the repertoire of bound peptides and binding by the TCR (22) . Such polymorphisms are thought to have evolved in response to infectious challenge (23) . NKG2D ligands are homologous to MHC molecules, and polymorphisms are focused within the MICA/B (21), ULBP4, and ULBP6 genes (18, 21, 24) . Single-nucleotide polymorphisms (SNPs) in NKG2D ligand-encoding genes are linked to human disease susceptibility and treatment outcome in several clinical disorders (25) (26) (27) (28) (29) (30) .
Most efforts to understand the functional importance of NKG2D ligand polymorphisms have focused on the valine-to-methionine dimorphism at position 129 of MICA, which is associated with overall survival after stem cell transplantation (SCT) (31) . This polymorphism in the region encoding the a2 domain of MICA is suggested to affect the avidity of NKG2D binding (31, 32) and the relative cell surface abundance of MICA (33) . These and other studies have contributed to the concept that MICA polymorphisms tune the strength of the NKG2D-mediated response to specific MICA variants and have also revealed highly variable responses between individuals (34) .
ULBP6 is one of the most recently discovered human NKG2D ligands and is highly polymorphic, with two haplotypes (ULBP0601 and ULBP0602) together making up~70% of the human population (18, 19) . ULBP6 polymorphisms are associated with diabetic nephropathy (27) , alopecia areata (AA) (29, 35) , and the clinical outcome after allogeneic hematopoietic SCT (25) . These studies highlight ULBP6 as an important immunoregulatory molecule and indicate the value of understanding the functional significance of the polymorphisms detected within the protein. We therefore undertook a detailed analysis of the biophysical, structural, and functional importance of polymorphisms within ULBP6, focusing on the ULBP0601/ULBP0602 dimorphism. We showed that a specific amino acid change within the ULBP0602 ectodomain had a substantial effect on the affinity of binding to NKG2D and resulted in an interaction with enhanced stability. This high-affinity interaction dampened the NKG2D-mediated activation of effector cells and reduced the magnitude of effector responses to target cells in all individuals tested. In addition, high-affinity soluble ULBP0602, which was released from the surface of ULBP0602-transfected cells, blocked the interaction between NKG2D and other ULBPs. Thus, ULBP6 polymorphism acts as a critical regulator of human lymphoid stress surveillance and may represent an important immunotherapeutic target.
RESULTS

ULBP6 is found on peripheral blood mononuclear cells and is increased in abundance in hematopoietic tumors
To understand the potential influence of allelic polymorphism (Fig. 1A) on the function of ULBP6, we first studied the pattern of ULBP6 expression by hematopoietic cells (Fig. 1B) . The currently used ULBP6-specific antibody also binds to ULBP2 and ULBP5, so we initially investigated the pattern of expression of the genes encoding these three ULBPs by quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of primary CD4 + and CD8 + T cells, NK cells, B cells, and monocytes. The specificity of these qRT-PCR assays was first validated ( fig. S1 ). HCT116 cells (a colorectal cancer cell line) were used as a positive control, whereas NKL, lymphoblastoid cell line (LCL), Jurkat, The relative abundances of ULBP6, ULBP2, and ULBP5 mRNAs in the indicated cell lines (HCT116 cells were a positive control for ULBP6, and NKL, LCL, Jurkat, and HeLa cells were negative controls for ULBP6) and PBMC-derived immune cell populations were determined by qRT-PCR analysis. Data are shown as mean copy numbers ± SEM of eight donors. Each symbol represents one donor or cell line, with the differences analyzed by one-way analysis of variance (ANOVA) with Dunn's multiple comparison posttest between the indicated groups (*P < 0.05 (Fig. 1B) . This amount of ULBP6 mRNA in B and NK cells was several fold greater than that of ULBP2 mRNA (median 7.1 and 18 copies per reaction, respectively), although high ULBP2 transcription was observed in several cell lines (200 to 2000 copies per reaction) (Fig. 1B) . ULBP5 mRNA was undetectable in almost all primary cells and cell lines (Fig. 1B) . Given this profile of expression within primary hematopoietic cells, we next determined the pattern of ULBP6 expression in a range of primary hematological tumors (Fig. 1,  C and D) . Several hematological malignancies express at least one member of the NKG2D ligand family, although ULBP6 has not yet been studied in this regard (36) . ULBP6 transcription was substantially and specifically increased in tumor cells from patients with a range of lymphoid malignancies including chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, large granular lymphocytic lymphoma, and PLPD (polymorphic lymphoproliferative disorder). Median ULBP6 mRNA abundance was about~5 times higher than that observed in peripheral blood mononuclear cells (PBMCs) from healthy control donors (Fig. 1C) .
To investigate how ULBP6 expression was altered in CLL, the most common subtype of leukemia, we compared transcriptional assays and anti-ULBP2/5/6 staining in healthy donor and primary CLL samples. qRT-PCR analysis demonstrated increases in ULBP6 transcription and, to a lesser extent that of ULBP2, in PBMCs from CLL samples, whereas ULBP5 mRNA was not detectable in either healthy donor samples or CLL samples (Fig. 1D ). In addition, statistically significantly more staining by antibody against ULBP2, ULBP5, and ULBP6 was observed on primary CLL tumor cells than on healthy donor B cells (Fig. 1, E and F). This increase was relatively modest, consistent with studies on MICA and ULBP1 to ULBP3, which have shown that NKG2D ligand expression is tightly controlled and that small alterations in NKG2D ligand abundance in response to stress stimuli can effectively modulate NKG2D-mediated responses (37) . Finally, we assessed whether the ULBP0601/ ULBP0602 polymorphism influenced the transcription of ULBP6 using sequencespecific polymorphism PCR as previously described (Fig. 1G) (25) . No statistically significant difference in ULBP6 expression was observed between the ULBP0601 and ULBP0602 genotypes within a cohort of hematological malignancy samples (Fig. 1G) , suggesting that allelic variation does not influence transcriptional regulation of ULBP6. Together, these results support ULBP6 being a bona fide stress-induced NKG2D ligand that is increased in abundance during tumorigenesis, but suggest that the ULBP0601/ULBP0602 polymorphism does not affect the stress-induced expression of ULBP6.
ULBP0602 has a high affinity for NKG2D
We next examined whether the ULBP06*01/02 polymorphism influenced the molecular properties of the interaction of the protein with NKG2D. To assess this, we expressed recombinant ULBP6 with amino acids characteristic of the 01 and 02 haplotypes at the two polymorphic positions in the MHC-like ectodomain [hereinafter termed ULBP0601 (containing Arg 106 and Ile
147
) and ULBP0602 (containing Leu 106 and Thr 147 )]. The biophysical characteristics of the interaction of these proteins with NKG2D were then assessed with surface plasmon resonance (SPR) (Fig. 2) . As expected, SPR detected the binding of NKG2D to the ligand. However, when the binding to ULBP0601, ULBP0602, and the other ULBPs was compared at similar immobilization values, disproportionately high binding responses and slow dissociation of NKG2D were observed for ULBP0602, indicating a particularly high affinity for this allelic form ( Fig. 2A) . It took more than 2 hours for 
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NKG2D to completely dissociate from immobilized ULBP0602 when a flow rate of 10 ml/min was used. Equilibrium affinity analyses (Fig. 2B ) determined an affinity of 15.5 nM for the ULBP0602-NKG2D interaction, which was more than 10-fold higher than the equivalent affinity of NKG2D for ULBP0601 (164.6 nM) and substantially greater than the affinities that we determined for the other ULBP family members ( fig. S2 ), which varied between about 300 nM and 35 mM (table S1 ). An affinity of~1 mM was reported for the binding of MICA/B to NKG2D (24) . Kinetic measurements confirmed an extremely slow dissociation for the ULBP0602 form, with a k off of~0.00125 s −1 (t 1/2 of~550 s) (Fig. 2C) , substantially slower than the NKG2D-ULBP0601 interaction, which exhibited a k off of 0.022 s −1 (t 1/2 of~31 s) (Fig. 2C ). These data indicate that the interaction between NKG2D and ULBP0602 is much stronger than that with ULBP0601 and the other ULBP family members.
A structure of the NKG2D-ULBP6 complex was solved to 2.4 Å To understand how ULBP0602 bound so strongly to NKG2D and to determine the biophysical correlate of the UBP0601/UBP0602 polymorphism, we next determined the structure of the NKG2D-ULBP0602 interaction by x-ray crystallography to 2.4 Å (Fig. 3, A and B, and table S2). The core structure of ULBP0602, including the topology of its NKG2D-binding surface, closely resembles that of ULBP3 [overall root mean square deviation (RMSD), 2.1 Å; Fig. 3C ], comprising two major helices atop an eight-stranded, antiparallel b sheet, with interlocking hydrophobic residues generating a narrower cleft than that of the class I MHC molecule, which is unsuitable for binding antigenic peptides (Fig. 3D) . Note that one-third (23) of the nonconservative substitutions relative to ULBP3 map onto the MHClike helical surface that serves as a primary contact site for NKG2D ( fig. S3A ).
Rigid body binding occurs within a conserved diagonal NKG2D interaction mode The NKG2D-ULBP0602 interaction broadly resembles that from previously solved NKG2D ligand structures, featuring the symmetric NKG2D homodimer bound to a monomeric ULBP0602 (Fig. 3A) through a diagonal mode similar to the NKG2D-ULBP3 (38) and NKG2D-MICA (39) structures and akin to the TCR-peptide-MHC (pMHC) interaction (Fig. 3E) . The saddle-shaped NKG2D homodimer sits astride the ULBP6 helices, with NKG2D monomers
β1 β1 β7 β2 A and B focused on the ULBP0602 a2 and a1 helices, respectively ( ) and TCR-pMHC (1700 to 1800 Å 2 ) interfaces. As noted for the NKG2D-ULBP3 interaction (38) , three secondary structural elements from each NKG2D monomer stabilize the interface: the L1 loop (residues L150 to D152), the b5-b5′ stirrup loop (residues M180 to S186), and the b6 strand (residues E195 to G200) (Fig. 3A) . Notwithstanding relatively minor conformational differences in the stirrup loop of ULBP6-bound NKG2D relative to either unbound NKG2D ( fig. S3B ) or ULBP3-bound NKG2D (fig. S3C), no major conformational changes were observed, which is reflected by the low RMSD values for the NKG2D chains (0.8 to 0.9 Å).
Analysis of the NKG2D-ULBP0602 interface contacts indicated that the number of polar contacts used by ULBP0602 was similar to that of ULBP3 (Fig. 4A, fig. S4 , and table S3). Note that the ULBP residues involved are not conserved within the family, either in position or identity, suggesting that family members use distinct combinations of interacting groups to bind to NKG2D ( fig. S5 ). However, two charged residues, Glu 96 and Asp
189
, conserved between ULBP3 and ULBP0602, are positioned in the center of the interface and oriented diagonally with respect to the a1 and a2 helices (Fig. 4B) fig. S5 ). It is tempting to speculate that they represent a conserved electrostatic orientation footprint, guiding NKG2D toward a diagonal mode of docking (Fig. 4B ).
Hydrophobic interactions mediate the high affinity of the NKG2D-ULBP6 interaction Hydrophobic contacts at the ULBP0602-NKG2D interface appear to play a defining role in determining the enhanced affinity of ULBP0602 relative to that of ULBP0601 and explain why ULBP0602 has the strongest interaction with NKG2D. The previous NKG2D-ULBP3 structure highlighted a hydrophobic patch on each NKG2D subunit (comprising Tyr ), which interacts with ULBP3 around the C-terminal ends of the a2 helix (subunit A, "patch A") and the a1 helix (subunit B, "patch B") (38) . Note that hydrophobic contacts to patch A are~3-fold enhanced in ULBP0602-NKG2D interface compared to those in the ULBP3-NKG2D interface, which is mediated by the substitution of , which is likely to invoke less energetic penalties in terms of binding to patch A as compared to ULBP3. Furthermore, the largely hydrophobic NKG2D patch B forms fewer contacts (~25% reduced) with ULBP6 than with ULBP3 (table S4) , which is determined mainly by numerous contacts to ULBP3 Leu 104 . However, as for patch A, in ULBP3, the orientation of a charged Arg 103 toward this hydrophobic region is likely to incur energetic penalties; in ULBP6, the equivalent residue is uncharged, favoring interaction.
The R106L polymorphism generates a hydrophobic hotspot that enhances the NKG2D-ULBP6 interaction Examination of ULBP0601/ULBP0602 allelic differences based on the NKG2D-ULBP6 structure indicated that the T147I change was unlikely to affect NKG2D binding, because this residue protrudes from the underside of the b sheet (Fig. 4D) . In contrast, the introduction of Leu 106 in ULBP0602, which is located at the receptor-ligand interface (Fig. 4D) , provides a clear rationale for enhanced affinity, because it inserts directly into the center of the hydrophobic patch B of NKG2D, forming numerous nonpolar contacts with surrounding residues (Tyr (Fig. 4 , C and E, and table S4). In contrast, ULBP0601 has a charged and lengthy arginine at this position, and although its side chain can be accommodated without apparent steric clashes, its introduction within this predominantly hydrophobic environment is likely to be detrimental for NKG2D binding (Fig. 4F) . To directly confirm the hypothesis that the 106 polymorphism was responsible for the higher affinity of ULBP0602 for NKG2D, relative to that of ULBP0601, we mutated both of the residues at the 147 and 106 positions of ULBP0602 to the residues found in ULBP0601. The ULBP0602-T147I mutant that retained Leu 106 exhibited an affinity for NKG2D (13.4 nM) that was comparable to that of wild-type (WT) ULBP0602 (13.4 nM), whereas the affinity of the ULBP0602-L106R mutant (148.3 nM) was comparable to that of ULBP0601 (148.2 nM), indicating that the threonine-to-isoleucine mutation at position 147 had no effect on affinity (Fig. 4G) . These results confirm the key role of polymorphism at position 106 in determining the high affinity of ULBP0602 for NKG2D.
ULBP0602 elicits less-efficient NKG2D-dependent cytotoxicity than does ULBP0601 To assess the relative functional activities of the ULBP0601 and ULBP0602 proteins, we next tested their ability to elicit cytotoxicity in a range of NKG2D + lymphocytes, namely, NK cells, ab T cells, and gd T cells. We therefore generated Chinese hamster ovary (CHO) cells expressing ULBP0601 and ULBP0602 variants for use as target cells (called CHO-ULBP0601 and CHO-ULBP0602, respectively) and used flow cytometric analysis to confirm that the cell lines had equivalent amounts of cell surface protein (Fig. 5A) .
To assess NKG2D-mediated cytotoxicity within PBMCs, we used an established assay (34) that involved mixing equal numbers of either carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled CHO-ULBP0601 or CHO-ULBP0602 cells with mock-transfected CHO cells labeled with a 670-nm fluorescent dye (CHO-controls) in the presence or absence of activated PBMCs (see Materials and Methods). After coincubation with PBMCs, the ratio of CHO-ULBP0601 or CHO-ULBP0602 cells to CHO-controls was measured to determine relative cytotoxicity (Fig. 5B) . Antibody-blocking experiments were used to confirm that such cytotoxicity was indeed NKG2D-dependent (Fig. 5B) . The ratio of CHO-ULBP0601 cells to CHO-controls was lower than the ratio of CHO-ULBP0602 cells to CHO-controls after coincubation with PBMCs, indicating that the CHO-ULBP0601 cells elicited greater killing than did the CHO-ULBP0602 cells (Fig. 5B) . To address donor-specific variation, we expanded the assay using PBMCs from 18 healthy donors. Although the overall level of killing observed varied substantially, for all donors, CHO-ULBP0601 cells elicited enhanced NKG2D-dependent killing relative to the CHO-ULBP0602 cells (mean killing of 42.6 and 30.4%, respectively; P < 0.001; Fig. 5C ). This stronger NKG2D-dependent killing elicited by the CHO-ULBP0601 cells was further confirmed by a 51 Cr-based assay, which highlighted more pronounced differences in cytotoxicity (>3-fold) at lower effector-to-target ratios ( fig. S6 ). The cytotoxicity to Jurkat-ULBP0601 and Jurkat-ULBP0602 cells did not differ ( fig. S7 ), which was possibly because of the expression of other NKG2D ligands on these cell lines.
These results suggest that the enhanced affinity of the NKG2D-ULBP0602 interaction led to relatively less-efficient cytotoxic activity of effector cells in response to ULBP0602-expressing cells compared to ULBP0601-expressing cells. To address this further, we next examined whether the exposure of NK cells to interactions with ULBP0602 could hinder the killing of CHO-0601 cells. Two combinations of CHO cell mixtures were established, consisting of a 1:1 mixture of either CHO-ULBP0601 and CHO-ULBP0602 cells or CHO-parental and CHO-ULBP0601 cells. The NK cell-mediated lysis of CHO-0601 cells was markedly reduced in the presence of ULBP0602-expressing target cells ( fig. S8 ), suggesting that engagement with ULBP0602 indeed inhibited the ability of the NK cells to kill the surrounding target cells.
We next combined direct detection of target cell recognition by measurement of CD107a degranulation with costaining of phenotypic markers to identify the nature of the responding NKG2D + cell populations. NK cells from healthy donor PBMCs showed substantial degranulation (20 to 40%) in response to CHO-ULBP6 cells compared to parental CHO-control cells (Fig. 5D ). In addition, the percentage of CD107a + NK cells and the MFI of CD107a staining was consistently greater after incubation with CHO-ULBP0601 target cells than after incubation with CHO-ULBP0602 cells. Because the degree of NK cell activation can also be regulated by the abundance of NKG2D ligand, we next assessed how the relative surface expression of ULBP0601 or ULBP0602 on target cells influenced NK activation. CHO cells were transiently transfected with different amounts of plasmids encoding ULBP0601 or ULBP0602 (5, 10, or 20 mg per 5 × 10 6 cells), which led to differential cell surface protein expression, although the amounts of ULBP0601 and ULBP0602 were comparable for a given amount of plasmid ( fig. S9A ). These CHO cells were then cocultured with primary NK cells, and NK cell activation was determined by measuring the intensity of CD107a staining. The intensity of CD107a staining was maximal upon coincubation with either the ULBP0601 or the ULBP0602 transfectants that received 10 mg of plasmid ( fig. S9B) . However, NK cell activation in response to coincubation with cells transfected with 10 or 20 mg of plasmid was markedly higher for the ULBP0601 target cells as compared to the ULBP0602 target cells ( fig. S9C ).
Soluble NKG2D ligands are able to block the engagement of NKG2D with its ligands (40) ; thus, we generated and purified soluble ULBP0601 and ULBP0602 proteins. These were initially incubated with NK cells for 16 hours before the pattern of NKG2D expression was assessed by flow cytometry. Soluble ULBP0602 blocked the binding of NKG2D-specific antibody to NKG2D, but this effect was not observed when the lower-affinity ULBP0601 protein was used in concentrations up to 10 mg/ml (Fig. 6, A and  B) . To determine whether this blockade had the potential to modulate NK cell function, we assessed the pattern of NK cell activation in response to K562 cells in the presence or absence of soluble ULBP6. We found that both ULBP0601 and ULBP0602 partially blocked NK cell activation by K562 cells and that this effect was more substantial after incubation with ULBP0602 than with ULBP0601 (Fig. 6C) . We therefore investigated whether soluble ULBP0601 or ULBP0602 is released into the conditioned medium of CHO transfectants and whether this contributed to the observed pattern of differential cellular activation. Low amounts of soluble ULBP0601 and ULBP0602 were indeed released into the culture medium after 12 hours of incubation and typically reached comparable concentrations (~400 pg/ml) for both variants (Fig. 6D) . To assess whether soluble ULBP6 blocked the binding of other soluble ligands to NKG2D, we incubated the NKL cell line with ULBP2-Fc protein in the presence or absence of conditioned medium from the ULBP06 transfectants. The extent of ULBP2-Fc binding to the NKL cells was measured by flow cytometric analysis using an anti-Fc antibody. Conditioned medium from both CHO-ULBP0601 and CHO-ULBP0602 transfectants partially blocked the binding of ULBP2-Fc to the NKL cell line, although this effect was more pronounced with CHO-ULBP0602 (37% inhibition compared to 14% by ULBP0601) (Fig. 6E ).
Next, we tested the effect of ULBP6 polymorphism on NKG2D-dependent gd and ab T cell responses. Human peripheral blood Vg9Vd2 T cells proliferated in response to (E)-4-hydroxy-3-methylbut-2-enyl pyrophosphate (HMB-PP), expressed high amounts of NKG2D (Fig. 7A) , and demonstrated enhanced killing of CHO-ULBP0601 cells compared to CHO-ULBP0602 cells, indicating differential costimulation of gd T cells responding to HMB-PP by ULBP06 variants (Fig. 7, B and C) . In addition, NKG2D
+ ab cytotoxic T cell clones (Fig. 7D ) specific for Epstein-Barr virus (EBV) epitopes restricted by HLA-B7 displayed substantially enhanced production of interferon-g (IFN-g) in response to cognate antigen-pulsed Jurkat cells (which naturally express HLA-B7) transfected with plasmid encoding ULBP0601 (Jurkat-ULBP0601 cells) compared to those expressing ULBP0602 (Jurkat-ULBP0602 cells) (Fig. 7E) , suggesting that ULBP6 polymorphism markedly influences the efficiency of HLA-restricted T cell costimulation (Fig. 7F) . In summary, polymorphisms in ULBP6 substantially influenced the strength of NKG2D-dependent effector responses, with the lower-affinity ULBP0601 allotype being more potent than the higher-affinity ULBP0602 allotype.
The functional potency of ULBP0602 is limited by polymorphism at position 106 We next tested whether altering the affinity of ULBP6 affected its potential to elicit NK cell cytotoxicity. After confirming NKG2D expression on the NKL cell line (Fig. 8A) , NKL-mediated cytotoxicity was assessed in the presence of a range of different target cell lines. These included CHO-ULBP0601 and CHO-ULBP0602 cells (Fig. 8B) , as well as CHO-ULBP0602-L106R and CHO-ULBP0602-T147I cells, which carried single-amino acid changes at positions 106 and 147 within ULBP0602 (Fig. 8C ). Competitive cytotoxic assays were then performed, and, as expected, NKL cells showed dose-dependent specific killing of CHO-ULBP0601 and CHO-ULBP0602 cells, with the CHO-ULBP0601 cells eliciting greater cytotoxicity than that elicited by the CHO-ULBP0602 cells (Fig. 8B) . The CHO-ULBP0602-L106R transfectant, which expressed a mutant of ULBP0602 with an NKG2D affinity matching that of ULBP0601, elicited greater cytotoxicity than did CHO-ULBP0602 cells and, indeed, was comparable to CHO-ULBP0601 cells (Fig. 8D, left) . In contrast, CHO-ULBP0602-T147I cells elicited comparable cytotoxic responses to those elicited by CHO-ULBP0602 cells (Fig. 8D, right) , suggesting that the Leu 106 SNP in ULBP0602 is responsible for both its high affinity for NKG2D and its limited functional potency relative to that of ULBP0601 (Fig. 8E) .
Differential NKG2D-ULBP6 affinities affect NKG2D signaling and receptor down-regulation To understand how differential NKG2D-ULBP6 affinities could lead to altered effector cell responses, we assessed NKG2D down-regulation (decreased cell surface expression), a surrogate indicator of receptor stimulation. After 1 hour of coculture with CHO-ULBP0601 cells, NKL cells showed~80% down-regulation of cell surface NKG2D (Fig. 8F ). In contrast, coculture with CHO-ULBP0602 cells resulted in substantially less receptor down-regulation (Fig. 8F) , and this difference persisted throughout the 16-hour time course. This finding reveals that ULBP0601 induced more efficient NKG2D down-regulation than did the higher-affinity ligand ULBP0602, which is suggestive of differential signaling. To address this, we assessed calcium flux after the engagement of NKG2D with either ULBP0601 or ULBP0602. NKL cells loaded with Calcium Sensor Dye were acquired by flow cytometry before and after exposure to CHO-ULBP0601 or CHO-ULBP0602 cells. Relative to their basal calcium concentration, NKL cells coincubated with CHO-ULBP0601 cells had statistically significantly increased free intracellular calcium concentrations compared to those in NKL cells coincubated with CHO-ULBP0602 cells (Fig. 8G) . NKG2D surface staining was analyzed by flow cytometry and quantified, and the differences were analyzed by two-way ANOVA with Bonferroni-corrected post hoc comparisons between the indicated groups. ***P < 0.001. Data are means ± SEM from three independent experiments. (C) Primary NK cells from six donors were cocultured with K562 cells with or without soluble ULBP0601 or ULBP0602 (10 mg/ml), and NK cell activation was quantified by the flow cytometric analysis of CD107a staining. The differences between the indicated groups were analyzed by oneway ANOVA with Tukey's multiple comparison posttest. **P < 0.01; ***P < 0.001. (D) The concentration of soluble ULBP6 released during the culture of CHO-ULBP0601 and CHO-ULBP0602 cells was quantified by enzyme-linked immunosorbent assay (ELISA). Data are means ± SEM from three independent experiments. (E) NKL cells were cultured with the conditioned medium from the indicated cells and then stained with ULBP2-Fc proteins followed by APC-conjugated anti-human Fc and flow cytometric analysis. Data are means ± SEM from three independent experiments. Differences were analyzed by Mann-Whitney test. *P < 0.05; **P < 0.01.
of infection and malignant disease. Notably, both ULBP and MIC proteins exhibit considerable polymorphism. However, the functional importance of these polymorphisms, the factors that have driven their selection, and how they might influence relevant disease mechanisms have remained largely unclear. We chose to focus on ULBP6 because this is the most polymorphic gene within the ULBP family, and SNPs within ULBP6 are associated with several clinical disorders (25, 27, 29) . We showed that the two common allelic variants of ULBP6, ULBP0601 and ULBP0602 (19, 25) , elicited distinct NKG2D-dependent responses and exhibited profound differences in the affinity of NKG2D binding, which resulted in differential capacity to activate effector cells. Specifically, engagement with ULBP0601 elicited substantially enhanced NKG2D-dependent responses relative to those elicited by ULBP0602. Although the extents of the differences in effector responses elicited by ULBP0601 and ULBP0602 were relatively modest (typically ≤30%, but up to~3-fold in chromium-release assays), these differences were observed in all NKG2D + effector subsets (NK cells, as well as ab and gd T cells), in relation to a range of different effector responses (cytotoxicity and cytokine production) and consistently across every individual tested. Thus, this common NKG2D ligand dimorphism can modulate the strength of NKG2D-mediated stress responses. We also outlined a previously uncharacterized molecular mechanism whereby this occurs, namely, through a key polymorphic amino acid change at position 106 (Arg→Leu), which affects the strength and stability of the NKG2D-ULBP6 interaction. Previous studies on MICA have highlighted high interindividual variation in NKG2D-mediated responses (34) , and the varying magnitude of the NK cell response that we observed between individuals is consistent with this. However, the hierarchy of responses to different polymorphic MICA variants was also found to vary between individuals (34) . In contrast, the existence of a dominant hierarchy of functional responses to the ULBP6 dimorphic variants conserved in all individuals tested (ULBP0601 > ULBP0602) hints at new mechanisms underpinning regulation of NKG2D-mediated responses.
Previously, ULBP6 polymorphism was linked to diabetic nephropathy (27) , autoimmune alopecia (29) , and differential clinical outcome after SCT (25) . Although the precise mechanisms that operate in each clinical scenario are unclear, we suggest that variability in the strength of NKG2D-mediated cellular responses contributes to such Data are means ± SEM from three independent experiments. Differences between the ULBP0601 and ULBP0602 cells were analyzed by two-way ANOVA with Bonferroni-corrected post hoc comparisons. *P < 0.05; **P < 0.01; ****P < 0.0001.
susceptibilities. Despite eliciting stronger effector responses compared to those elicited by ULBP0602, the ULBP0601 variant is associated with reduced survival after SCT (25) , perhaps suggesting that enhanced NK cell-mediated reduction in tumor antigen availability or elimination of antigen-presenting cells (41) (42) (43) (44) or T cells (45, 46) suppresses the subsequent development of alloreactive T cell immunity. Note that ULBP0602 mediated reduced NKG2D-mediated responses when expressed at the cell surface and in soluble form was a more potent suppressor of such responses than was ULBP0601. Our observation of increased ULBP6 expression in hematological tumor cells is consistent with the first model, and future studies may suggest novel immunotherapeutic strategies based on these concepts involving NKG2D-ULBP6-targeted immunomodulation after SCT and/or complementary vaccination or adoptive cell transfer approaches.
AA is a T cell-driven autoimmune condition (47, 48) , and a ULBP6 SNP (rs9479482) is strongly associated with this condition, with the highest odds ratio of any locus outside the MHC (29, 35) . Consistent with this, NKG2D + T cells are critical mediators in initiating AA (48) , and ULBP3 abundance is increased in hair follicles during active disease (29) . Another ULBP6 SNP (rs1543547) showed the strongest linkage among >11,000 SNPs analyzed for association with diabetic nephropathy, which is now a leading cause of renal failure and necessity of dialysis (27) . Although previous studies have highlighted the important contribution of NKG2D + T cells to nephropathy, the pattern of expression of ULBP6 has not yet been examined (49) . These genetic associations, combined with our finding that ULBP6 can act as an important costimulatory molecule for T cell recognition, support a role for pathogenic cytotoxic T cell responses in susceptible individuals and suggest that local expression of ULBP6 in the skin and kidney may be of considerable clinical importance.
The molecular mechanisms whereby the ULBP0601/ULBP0602 polymorphism influences NKG2D-mediated responses are also of interest. The NKG2D-ULBP0602 structure revealed that, by inserting into a nonpolar pocket in NKG2D, the R106L polymorphism contributes to a distinct interface featuring a double hydrophobic hotspot. This may explain why ULBP0602 has the highest affinity for NKG2D of all of the NKG2D ligands, with a value that is >10-fold higher than that of ULBP0601. This structure also sheds light on NKG2D recognition in general, where previous studies have invoked either "induced fit" or "rigid body adaptation" (38, 39) mechanisms to explain the remarkable ability of NKG2D to interact with eight relatively diverse ligands (ULBP1 to ULBP6, MICA, and MICB). Notwithstanding relatively minimal conformational alterations in NKG2D upon ULBP6 engagement, our structural data indicate that ULBP6 and ULBP3 use very distinct molecular mechanisms of binding to NKG2D, which is consistent with rigid body adaptation (39) . Moreover, our data reveal that underlying these diverse interaction profiles is a conserved electrostatic core comprising Glu 96 and Asp 189 on ULBP6, which interact with lysine residues in patches A and B on NKG2D, respectively. These two negatively charged residues are conserved across the entire ULBP family, and their diagonal orientation most likely guides NKG2D to dock in its diagonal binding mode. Our data thus suggest that a conserved "electrostatic restriction" to NKG2D ligand underpins the degenerate recognition by NKG2D of its diverse ligands. Our results may also explain how the substantial differences in affinity and kinetics in the interactions between NKG2D and ULBP0601 or ULBP0602 translate into differential functional effects. ULBP0602 exhibited a higher affinity than that of ULBP0601 for NKG2D but engendered weaker NKG2D-mediated responses. One possibility is that the generation of soluble forms of ULBP06 underlies these functional differences. Consistent with this, we demonstrated that soluble recombinant ULBP0602 exhibited strong binding to NKG2D and had the potential to competitively inhibit NKG2D binding to alternative NKG2D ligands, leading to a greater relative suppression of NKG2D-mediated effector cell responses compared to ULBP0601. This effect was observed to a modest extent with the use of conditioned medium from ULBP6-expressing transfected cell lines (Fig. 6, D and E) , suggesting that cleavage of the ligand from the cell surface may play an important physiological role in vivo (13, 40) . A second mechanism that may operate relates to the stable nature of the NKG2D-ULBP0602 interaction, which equates to a t 1/2 of~550 s at 25°C, and is likely to limit serial triggering of NKG2D molecules at the surface of the effector cell. In contrast, the faster k off for ULBP0601, equating to a t 1/2 of 31 s at 25°C, could elicit much more efficient serial triggering of NKG2D. Serial triggering of TCRs by pMHC molecules is required for TCR down-regulation and the intracellular signaling events that lead to activation (50, 51) . The more efficient down-regulation of NKG2D molecules elicited by ULBP0601 suggests that NKG2D serial triggering is likely to be the key discriminator between ULBP0601 and ULBP0602, translating differential binding kinetics into distinct functional responses. Consistent with this, enhanced calcium fluxes were observed after NKG2D engagement by ULBP0601 relative to those stimulated by engagement with ULBP0602. Although it is unclear to what extent soluble ULBP6-mediated inhibition versus differential serial triggering effects drive the distinct biology of the two isoforms in vivo, our results highlight that, as for the TCR (51), the molecular properties of the NKG2D-ligand interaction play a key role in determining the efficacy of NKG2D-mediated effector cell responses. Our findings raise questions about the evolutionary selection of the ULBP0601 and ULBP0602 alleles. Their coexistence at broadly equivalent and high frequencies, and their presence in diverse human populations, including Euro-Caucasoid, Afro-Caribbean, Indo-Asian (18) , and an indigenous South American tribe (52) , suggest that they arose in ancestral human populations and that the strength of NKG2D-mediated responses is the subject of strong and persistent evolutionary selection pressure. ULBP6 and ULBP4 are the only polymorphic ULBP molecules within the Kolla South American Indians, and they exhibit linkage disequilibrium, indicating a potential selective advantage (52) . One possibility is that different immunological challenges, such as protection against infection and immunological tolerance in pregnancy, may favor selection of these different forms. This potentially mirrors the evolution of KIR genes, whereby the balance of activating and inhibitory KIRs is thought to result from the action of similar environmental influences (53) . NK cells within the decidua do indeed express ULBP (54) , and as such, polymorphism may influence reproductive success. Persistence of the ULBP0601/ULBP0602 dimorphism could also result from balancing selection, a phenomenon that is thought to have helped drive MHC allelic diversity because heterozygosity has an adaptive advantage over homozygosity. Conceivably, weaker NKG2D-mediated responses in ULBP0602 homozygotes may compromise pathogen resistance, whereas ULBP0601 homozygosity may impair immunological tolerance. Consistent with ULBP0601/ ULBP0602 heterozygotes displaying a distinct immunological phenotype, heterozygote survival after SCT is intermediate compared to that of ULBP0601 and ULBP0602 homozygotes (25) . This observation suggests that therapeutically modulating the strength of NKG2D-mediated responses could be a viable route to improve patient outcomes both in SCT and other settings.
The considerable polymorphism within ULBP6 and the association of these alleles, including ULBP0601 and ULBP0602, with several clinical disorders suggest that this member of the NKG2D ligand family may represent an important therapeutic target (25, 27, 29, 35) . However, rational interventions will require a more advanced understanding of the immunological mechanisms involved. This would include a better appreciation of how the strength of NKG2D-mediated responses affects the potency of alloreactive T cell responses after SCT (25) . Similarly, an improved understanding of the regulation of ULBP6 expression in the context of autoimmunity (27, 29, 35) could shape future therapeutic ideas. On the basis of the results of such clinical studies, rational interventions that seek to modulate the strength of ULBP6-focused effector responses within specific disorders may represent an important and unexpected source of novel immunotherapeutic approaches (55) .
MATERIALS AND METHODS
Quantification of ULBP transcripts by qRT-PCR
Total RNA was isolated from whole PBMCs or purified lymphocyte populations with the Qiagen RNeasy Kit and was treated with DNase (deoxyribonuclease) I (TURBO DNA-free Kit; Ambion). qRT-PCR assays for ULBP2, ULBP5, and ULBP6 (ULBP2: Hs00607609-mH; ULBP5: Hs01584111-mH; and ULBP6: Hs04194671-s1) were performed with TaqMan Cell culture, cell lines, antibodies, and flow cytometric analysis ULBP0601 and ULBP0602 constructs were generated by site-directed mutagenesis, and cDNAs were subcloned into the pcDNA5/FRT vector. The Flp-In-CHO and Flp-In-Jurkat cell lines were purchased from Invitrogen and maintained in Ham's F12 medium (Invitrogen) containing 10% fetal calf serum (FCS), penicillin (100 IU/ml), streptomycin (100 mg/ml), and Zeocin (100 mg/ml), and in RPMI (Sigma) containing 10% FCS, penicillin, streptomycin, and Zeocin (100 mg/ml), respectively. The Flp-In-CHO cell line was transfected with ULBPencoding plasmids with Lipofectamine LTX (Invitrogen), whereas Jurkat cell lines were transfected by electroporation, together with the pOG44 plasmid encoding the Flp-In recombinase. The stable transfectants were selected with hygromycin (500 mg/ml). The NKL cell line was maintained in RPMI 1640, 10% FCS, and antibiotics with
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IL-2 (100 U/ml). PBMCs were isolated by Ficoll gradient. Blood samples from healthy donors were collected after informed consent was obtained. CD4 + T cell, CD8 + T cell, B cell, monocyte, and NK cell populations were separated with the EasySep Human T Cell Enrichment Kit (STEMCELL Technologies). Cell surface expression of ULBP6 or NKG2D on viable cells was determined by staining with APC-conjugated antibody against ULBP2/5/6 or isotype control antibody (R&D Systems) or with APC-conjugated antibody against NKG2D or isotype control (BD Biosciences). Stained cells were analyzed on a BD Accuri C6 flow cytometer, and the data were processed with FlowJo software (Tree Star). APC-conjugated anti-CD3, fluorescein isothiocyanate (FITC)-conjugated mouse anti-CD107a, phycoerythrin (PE)-conjugated mouse anti-CD56, and PE-conjugated mouse anti-CD8 antibodies were purchased from eBioscience. PEconjugated anti-TCR pan gd was purchased from Beckman Coulter. Dye eFluor 670 and CFSE were purchased from eBioscience. For calcium flux analysis, NKL cells were harvested, washed, and loaded with Calcium Sensor Dye eFluor 514 (eBioscience) for 30 min at 37°C. NKL cells were then analyzed by flow cytometry (BD Accuri C6) for 1 min, removed for the addition of CHO-ULBP0601 or CHO-ULBP0602 cells, and immediately placed back on the flow cytometer for continued data acquisition.
NK cell cytotoxicity assays The 1:1 mixture of ULBP0601 or ULBP0602 transfectants labeled with CFSE and control-transfected CHO cells labeled with Cell Proliferation Dye eFluor 670 were coincubated with effector cells (IFN-a-activated PBMCs) for 16 hours. After coculture, the ratio of CFSE-negative cells (647 dye-positive, control CHO cells) to CFSE-positive cells (ULBP0601 and ULBP0602 transfectant CHO cells) was calculated to determine the percentage of specific killing of each individual experiment. Lysis was calculated as follows: % specific lysis = 100 × {1 − [(control ratio)/(experimental ratio)]}. The control ratio refers to the ratio of CFSE-negative to CFSE-positive cells in the absence of effector cells, whereas the experimental ratio refers to the ratio of CFSEnegative to CFSE-positive cells in the presence of effector cells. Transfected CHO cell lines and IFN-a-activated PBMCs were cocultured with FITC-conjugated anti-CD107a antibody for 5 hours. The cells were then washed and stained with combinations of APCconjugated anti-CD3 and PE-conjugated anti-CD56 antibody to identify the NK cell population in the culture. Stained cells were analyzed on a BD Accuri C6 flow cytometer, and the data were processed with the FlowJo software (Tree Star).
T cell culture and effector cell assays ab T cell recognition was tested against Jurkat cell lines stably expressing ULBP0601 and ULBP0602, which were generated with the FRT-recombinase system as described earlier. For these assays, an HLA-B7-restricted, EBV-specific CD8 + T cell clone (specific for the BNRF1-derived epitope YPR (YPRNPTEQGNI) and generated in our own laboratory) was used and cultured in RPMI 1640 medium supplemented with 10% FCS, 30% supernatant from the IL-2-producing MLA-144 cell line, and recombinant IL-2 (50 U/ml). The capacity of the CD8 + T cell clone to recognize target cells was measured by IFN-g ELISA. The Jurkat-ULBP0601 cells and Jurkat-ULBP0602 cells were pulsed with serially diluted, synthetic YPR peptide and were used as targets in T cell assays with the YPR CD8 + T cell clone. Briefly, 10 4 effector T cells were incubated for 18 hours at 37°C in microtest plate wells with 10 5 target cells before assaying the supernatants for IFN-g release by ELISA (Endogen) in accordance with the manufacturer's recommended protocol. Peripheral blood Vd2 + T cells were expanded from healthy donor PBMCs with 10 nM HMB-PP (Sigma) and IL-2 (100 U/ml) (Miltenyi) for 14 days and purified by magnetic bead isolation (Miltenyi) by selecting for TCR Vd2 + cells (123R3, Miltenyi). For gd T cell killing assays, parental CHO cells (eFluor 670-labeled) and CHO cells stably expressing either ULBP0601 or ULBP0602 (CFSE-labeled) were mixed 1:1 and cocultured with the expanded purified Vd2 + T cells at various effector-to-target ratios in the presence of medium or 1 nM HMB-PP and IL-2 (40 U/ml) for 18 hours. Specific killing of CHO cells was monitored by staining with the amine reactive dead cell marker Zombie Aqua (BioLegend).
Shedding of ULBP6 from CHO-ULBP6 cells and blocking of NKG2D ligand binding The culture medium from overnight (12-hour) culture of CHOparental, CHO-ULBP0601, and CHO-ULBP0602 cells was harvested and analyzed with a Human ULBP-2 DuoSet ELISA Kit (DY1298, R&D Systems). The concentration of ULBP6 was calibrated according to the recommendation from the product datasheet: A sample containing rhULBP-6 (1.56 ng/ml) reads as 435 pg/ml (27.9% crossreactivity). For the blocking of the NKG2D ligand binding assay, NKL cells were cultured with the conditioned medium from both cultures and then stained with ULBP2-Fc proteins, which was followed by incubation with APC-conjugated anti-human Fc and analysis by flow cytometry.
SPR assays
SPR was performed at 25°C on a Biacore 3000 in HBS-EP (10 mM Hepes, 150 mM sodium chloride, 3 mM EDTA, and 0.005% polysorbate 20) essentially as described previously (56) . For these experiments, recombinant NKG2D was expressed in E. coli and purified, and ULBP proteins were expressed in the Drosophila expression system, with or without terminal His-tag/BirA biotinylation tags as appropriate. Equilibrium affinity measurements were conducted at 5 to 10 ml/min, and K d values were obtained either by Scatchard plots or by nonlinear curve fitting of the Langmuir binding isotherm [bound = C*max/(K d + C), where C is the analyte concentration and max is the maximum binding response] to data using the Levenberg-Marquardt algorithm as implemented in Origin 2015 (OriginLab Corporation). Concentrations of NKG2D and ULBPs were calculated as described previously (57) . For experiments comparing the interaction of NKG2D with ULBP0601 and ULBP060602, NKG2D was injected over streptavidin-coated CM5 surfaces on which biotinylated ULBP0601 or ULBP060602 complexes were immobilized. Streptavidin-coated surfaces left blank or coated with endothelial protein C receptor produced in the Drosophila expression system were used as negative controls. The K d values for the NKG2D-ULBP0601 and NKG2D-ULBP0602 interactions in this orientation were 164.6 ± 46 and 15.5 ± 4.3 nM, respectively (n = 14 and n = 10 measurements, respectively). Equilibrium affinity measurements conducted similarly in the opposite orientation confirmed similar affinities (136.5 and 11.2 nM for the NKG2D-ULBP0601 and NKG2D-ULBP0602 interactions, respectively). For most other NKG2D-ULBP interaction measurements, ULBP molecules were injected over immobilized NKG2D molecules or E. coliproduced HLA-A2 refolded with the Wilms' tumor protein (WT1)-derived peptide (RMFPNAPYL). For analysis of the effects of mutations at positions 106 and 147 on NKG2D interaction (Fig. 4G ), NKG2D was injected over ULBP0602, ULBP0602-T147I, ULBP0602-L106R, or a control protein. In a second, separate experiment, NKG2D was injected over ULBP0601, ULBP0602-T147I, ULBP0602-L106R, or a control protein. Figure 4G includes data from the two closely matched interactions (ULBP0602 and ULBP0602-T147I surfaces from the first experiment; ULBP0601 and ULBP0602-L106R from the second), with control responses subtracted. Immobilization values were similar between ULBP0601 and ULBP0602-L106R (960 and 974 RU, respectively) but marginally higher for ULBP0602 than ULBP0602-T147I (1036 and 967 RU, respectively), which could explain the higher binding responses to the ULBP0602 surface. Kinetic measurements to determine NKG2D-ULBP6 dissociation rate constants were performed with NKG2D as the analyte, using a flow rate of 50 ml/min to minimize mass transport considerations. Dissociation data were fitted to single exponential decay curves using the Langmuir 1:1 dissociation model as implemented in BIAevaluation 4.1.1 (GE Healthcare) and conformed to single-order kinetics.
Protein expression, purification, and crystallization For structural studies, the ectodomains of human NKG2D (residues Asn 80 to Val
216
) and ULBP0602 (residues Asp 29 to Pro 207 ) were both expressed in E. coli Rosetta cells as inclusion bodies and then reconstituted in vitro. To facilitate correct refolding of ULBP0602, C34, which does not contribute to the canonical ULBP family intramolecular disulfide bond formation, was mutated to serine with the QuikChange Kit (Stratagene). Analysis of the final NKG2D-ULBP0602 structure confirmed that the side chain at position 24 was entirely solventexposed. In brief, NKG2D or ULBP0602 was expressed from pET23a plasmids at 37°C, purified from inclusion bodies as described previously (56) , and then solubilized in 6 M guanidine hydrochloride before undergoing renaturation. NKG2D and ULBP0602 were then renatured separately by dilution refolding, which was performed with a refolding buffer consisting of 0.5 M L-arginine, 2.5 mM oxidized glutathione, 5 mM reduced glutathione, 0.1 M PMSF (phenylmethylsulfonyl fluoride), and 100 mM tris (pH 8). Renatured NKG2D and ULBP0602 were then independently purified on a Superdex 200 column. ULBP0602 protein was further purified by anion exchange with a Resource Q column before crystallization, in 20 mM tris (pH 8) and 5 mM NaCl, and eluted over a 1 M NaCl gradient. Purified ULBP0602 and NKG2D proteins were concentrated and mixed in a 1:1 molar ratio. Initial crystallization screening was performed using the hanging drop vapor diffusion method with the Mosquito nanoliter crystallization robot (TTP LabTech). NKG2D-ULBP0602 complex crystals formed after 3 to 4 days at 24°C with the PACT screen (Molecular Dimensions) condition 26, which consisted of 0.1 M PCB (sodium propionate, sodium cacodylate, and bis-tris propane) buffer (pH 5) and 25% PEG (polyethylene glycol) 1500 at an overall protein concentration of 9.9 mg/ml. Data collection, structure determination, and refinement NKG2D-ULBP0602 complex crystals were mounted directly from the mother liquor and flash-cooled in liquid nitrogen. X-ray diffraction data were collected to 2.4 Å resolution using an in-house MicroMax 007HF rotating anode Rigaku X-ray generator with a Saturn CCD detector. The NKG2D-ULBP0602 complex crystallized in the monoclinic space group C2, with one NKG2D-ULBP0602 complex per asymmetric unit, and unit cell parameters a = 82.3 Å, b = 82 Å, c = 73.2 Å, and b = 106.5°. All data were processed with XDS (58), with the relevant statistics listed in table S2. The complex structure was solved by molecular replacement using MOLREP (59) , with the NKG2D-ULBP3 complex as the search model [PDB code: 1KCG (38) ]. Refinement was performed with CNS (60) and REFMAC5 (61) interspersed with rounds of model building using COOT (62) . Electron density maps were well defined, enabling all amino side chains to be built. The stereochemical and refinement parameters are listed in table S2. All calculations relating to model validation, model analysis, and structure comparisons were performed with PROCHECK (63), programs of the CCP4 suite, and the Uppsala Software Factory (64) . All nonglycine residues are found in the allowed regions of the Ramachandran plot. Models of ULBP family members 1, 2, 4, and 5 were generated with the ULBP0602 structure as the template with the Phyre server (65) . Electrostatic surface potential maps were calculated with DelPhi (66) . Structural figures were generated with PyMOL.
Statistical analysis
For univariate analyses, where data did not follow a normal distribution, either Mann-Whitney U test (for unpaired data) or Wilcoxon matchedpairs signed rank test (for paired data) was used. Where data followed a normal distribution, the data were analyzed by either paired or unpaired, two-tailed t tests. Where there were multiple independent variables, they were categorized and then analyzed by either oneway or two-way ANOVA with Bonferroni post hoc test. All analyses were performed with Prism version 6.0 (GraphPad software).
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/10/481/eaai8904/DC1 Fig. S1 . Validation of the specificity of the ULBP2, ULBP5, and ULBP6 qRT-PCR assays. Fig. S2 . SPR analysis of NKG2D-ULBP interactions. Fig. S3 . Structural characteristics of the NKG2D-ULBP0602 complex. Fig. S4 . Stabilization of the NKG2D-ULBP3 complex interface. Fig. S5 . Sequence alignment of the ULBP family members. Fig. S6 . ULBP0601 elicits stronger cytotoxicity than does ULBP0602 in a 51 Cr-based assay. Table S1 . Comparison of the affinities of NKG2D for different NKG2D ligands. Table S2 . Data processing and refinement statistics for the NKGD2-ULBP0602 complex. Table S3 . Interactions mediated by polar residues at the NKGD2-ULBP6 interface. Table S4 . Comparison of the hydrophobic and van der Waal's contacts that stabilize the NKG2D-ULBP0602 and NKG2D-ULBP3 interfaces.
